COVID-19

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other…

7 months ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into…

7 months ago

New Survey: 84% of Respondents Would Participate in a Hospital-at-Home Program In Order To Get Home Sooner

Vivalink's survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of…

7 months ago

Cosmos Health Completes Acquisition of Pelofarm’s Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million

CHICAGO, IL / ACCESSWIRE / June 13, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

7 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to…

7 months ago

Koda Health Secures New Funding to Expand Advance Care Planning Capabilities

Led by Ecliptic Capital with strategic investment from Memorial Hermann Health System, AARP and the Texas Medical Center Venture Fund…

7 months ago

Affimed Reports First Quarter 2024 Financial Results & Business Update

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of…

7 months ago

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading…

7 months ago

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative…

7 months ago

Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the…

7 months ago